New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 239-257

  Mudaliar, S ^a   Henry, R R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Insulin sensitizers; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE CONTROL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; HYPERCOAGULABILITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; UNITED STATES;

CARDIOVASCULAR DISEASES; CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0035124186     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.239     Document Type: Review

References (73)

1. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults
2. The NIDDM epidemic: Global estimates and projection: A look into the crystal ball
3. Pathogenesis of NIDDM: A balanced overview
4. The cardiovascular dysmetabolic syndrome
5. Metabolic and vascular effects of the thiazolidinedione, troglitazone
6. Thiazolidinediones in the treatment of insulin resistance in type 2 diabetes
7. Peroxisome proliferator-active receptors: A nuclear receptor signaling pathway in lipid physiology
8. The structure-activity relationship between peroxisome-proliferator-activated receptor agonism and the antihyperglycemic activity of thiazolidinediones
9. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes
10. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes
11. Thiazolidinedione repress ob gene expression in rodents via activation of peroxisome proliferator activated receptor
12. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor alpha on differentiation, insulin stimulated glucose uptake, and gene expression in 3T3-L1 cells
13. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
14. The effects of spontaneous obesity on insulin binding, glucose transport and glucose oxidation of isolated rat adipocytes
15. Troglitazone action is independent of adipose tissue
16. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells
17. Troglitazone effects on gene expression in human skeletal muscle of type 2 diabetic subjects involve upregulation of PPAR gamma
18. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type 2 diabetic subjects
19. Expression and function of PPARgamma in rat and human vascular smooth muscle cells
20. Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension
21. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
22. + mobilization and cell proliferation in vascular smooth muscle cells
23. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)gamma activator troglitazone
24. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
25. Rosiglitazone short-term monotherapy lowers fasting and postprandial glucose in patients with type II diabetes
26. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
27. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients
28. Pioglitazone is effective in the treatment of patients with type 2 diabetes
29. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes
30. Combination therapy with metformin and pioglitazone in patients with type 2 diabetes
31. Combination therapy with insulin and pioglitazone in patients with type 2 diabetes
32. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy
33. Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells
34. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis
35. Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus
36. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
37. Dyslipoproteinemia and diabetes
38. Insulin resistance implications for type II diabetes and coronary artery disease
39. The effects of pioglitazone on the lipid profile in patients with type 2 diabetes
40. Troglitazone decreases the proportion of small dense LDL and increases the resistance of LDL to oxidation in obese subjects
41. Troglitazone and small low-density lipoprotein in type 2 diabetes
42. Increase of lipoprotein (a) with troglitazone
43. Etiology and prevalence of hypertension in diabetic patients
44. Hemodynamic actions of insulin
45. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans
46. Cardiac and glycemic benefits of troglitazone treatment in NIDDM
47. Rosiglitazone improves blood pressure in patients with type 2 diabetes
48. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus
49. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPAR gamma in endothelial function
50. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus
51. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism
52. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization
53. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells
54. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes
55. Expression and function of PPAR gamma in rat and human vascular smooth muscle cells
56. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect
57. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
58. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
59. Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity
60. Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: A serial intravascular ultrasound study
61. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholeterolemic Mediterranean population: The carotid atherosclerosis Italian ultrasound study
62. Kupio atherosclerosis prevention study (KAPS): A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries
63. Vasculo-protective effects of insulin-sensitizing agent pioglitazone in neointimal thickening and chronic hypertension
64. Insulin sensitivity and atherosclerosis
65. Effect of troglitazone on B cell function, insulin sensitivity and glycemic control in subjects with type 2 diabetes mellitus
66. Thiazolidinediones: An update
67. Hepatocellular injury in a patient receiving rosiglitazone. A case report
68. Hepatic failure in a patient taking rosiglitazone
69. Thiazolidinediones: An update
70. Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501